nodes	percent_of_prediction	percent_of_DWPC	metapath
Nelarabine—Nucleic Acid Synthesis Inhibitors—Azathioprine—systemic scleroderma	0.881	1	CiPCiCtD
Nelarabine—DGUOK—smooth muscle tissue—systemic scleroderma	0.00209	0.147	CbGeAlD
Nelarabine—DGUOK—digestive system—systemic scleroderma	0.00165	0.116	CbGeAlD
Nelarabine—DGUOK—tendon—systemic scleroderma	0.00157	0.111	CbGeAlD
Nelarabine—DGUOK—lung—systemic scleroderma	0.00138	0.0971	CbGeAlD
Nelarabine—ADA—connective tissue—systemic scleroderma	0.00131	0.0921	CbGeAlD
Nelarabine—POLA1—tendon—systemic scleroderma	0.000971	0.0682	CbGeAlD
Nelarabine—ADA—digestive system—systemic scleroderma	0.000946	0.0665	CbGeAlD
Nelarabine—ADA—tendon—systemic scleroderma	0.0009	0.0633	CbGeAlD
Nelarabine—POLA1—lung—systemic scleroderma	0.000852	0.0599	CbGeAlD
Nelarabine—ADA—lung—systemic scleroderma	0.00079	0.0556	CbGeAlD
Nelarabine—DCK—digestive system—systemic scleroderma	0.000629	0.0442	CbGeAlD
Nelarabine—DCK—tendon—systemic scleroderma	0.000599	0.0421	CbGeAlD
Nelarabine—DCK—lung—systemic scleroderma	0.000525	0.0369	CbGeAlD
Nelarabine—DCK—Desoximetasone—Mometasone—systemic scleroderma	0.000521	0.328	CbGdCrCtD
Nelarabine—DCK—Diflorasone—Mometasone—systemic scleroderma	0.000505	0.319	CbGdCrCtD
Nelarabine—DCK—Desoximetasone—Prednisone—systemic scleroderma	0.000284	0.179	CbGdCrCtD
Nelarabine—DCK—Diflorasone—Prednisone—systemic scleroderma	0.000275	0.174	CbGdCrCtD
Nelarabine—Infection—Leflunomide—systemic scleroderma	0.000126	0.00122	CcSEcCtD
Nelarabine—Vision blurred—Lisinopril—systemic scleroderma	0.000126	0.00122	CcSEcCtD
Nelarabine—Gastrointestinal pain—Captopril—systemic scleroderma	0.000126	0.00122	CcSEcCtD
Nelarabine—Asthenia—Mometasone—systemic scleroderma	0.000126	0.00122	CcSEcCtD
Nelarabine—Eye disorder—Mycophenolate mofetil—systemic scleroderma	0.000126	0.00122	CcSEcCtD
Nelarabine—Hypotension—Azathioprine—systemic scleroderma	0.000125	0.00122	CcSEcCtD
Nelarabine—Tremor—Lisinopril—systemic scleroderma	0.000125	0.00121	CcSEcCtD
Nelarabine—Cardiac disorder—Mycophenolate mofetil—systemic scleroderma	0.000125	0.00121	CcSEcCtD
Nelarabine—Nervous system disorder—Leflunomide—systemic scleroderma	0.000124	0.00121	CcSEcCtD
Nelarabine—Thrombocytopenia—Leflunomide—systemic scleroderma	0.000124	0.0012	CcSEcCtD
Nelarabine—Anaemia—Lisinopril—systemic scleroderma	0.000123	0.0012	CcSEcCtD
Nelarabine—Musculoskeletal discomfort—Azathioprine—systemic scleroderma	0.000122	0.00119	CcSEcCtD
Nelarabine—Confusional state—Mycophenolic acid—systemic scleroderma	0.000122	0.00118	CcSEcCtD
Nelarabine—Angiopathy—Mycophenolate mofetil—systemic scleroderma	0.000122	0.00118	CcSEcCtD
Nelarabine—Abdominal pain—Captopril—systemic scleroderma	0.000122	0.00118	CcSEcCtD
Nelarabine—Body temperature increased—Captopril—systemic scleroderma	0.000122	0.00118	CcSEcCtD
Nelarabine—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000121	0.00117	CcSEcCtD
Nelarabine—Oedema—Mycophenolic acid—systemic scleroderma	0.000121	0.00117	CcSEcCtD
Nelarabine—Anorexia—Leflunomide—systemic scleroderma	0.000121	0.00117	CcSEcCtD
Nelarabine—Nausea—Pentoxifylline—systemic scleroderma	0.000121	0.00117	CcSEcCtD
Nelarabine—Chills—Mycophenolate mofetil—systemic scleroderma	0.000121	0.00117	CcSEcCtD
Nelarabine—Infection—Mycophenolic acid—systemic scleroderma	0.00012	0.00116	CcSEcCtD
Nelarabine—Diarrhoea—Mometasone—systemic scleroderma	0.00012	0.00116	CcSEcCtD
Nelarabine—Hypokalaemia—Prednisone—systemic scleroderma	0.00012	0.00116	CcSEcCtD
Nelarabine—Leukopenia—Lisinopril—systemic scleroderma	0.000119	0.00116	CcSEcCtD
Nelarabine—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.000119	0.00115	CcSEcCtD
Nelarabine—Hypotension—Leflunomide—systemic scleroderma	0.000118	0.00115	CcSEcCtD
Nelarabine—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	0.000118	0.00115	CcSEcCtD
Nelarabine—Mental disorder—Mycophenolate mofetil—systemic scleroderma	0.000118	0.00114	CcSEcCtD
Nelarabine—Loss of consciousness—Lisinopril—systemic scleroderma	0.000117	0.00114	CcSEcCtD
Nelarabine—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.000117	0.00113	CcSEcCtD
Nelarabine—Cough—Lisinopril—systemic scleroderma	0.000116	0.00113	CcSEcCtD
Nelarabine—Muscular weakness—Prednisone—systemic scleroderma	0.000116	0.00113	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000116	0.00112	CcSEcCtD
Nelarabine—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.000115	0.00112	CcSEcCtD
Nelarabine—Anorexia—Mycophenolic acid—systemic scleroderma	0.000115	0.00112	CcSEcCtD
Nelarabine—Insomnia—Leflunomide—systemic scleroderma	0.000115	0.00111	CcSEcCtD
Nelarabine—Abdominal distension—Prednisone—systemic scleroderma	0.000115	0.00111	CcSEcCtD
Nelarabine—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	0.000114	0.00111	CcSEcCtD
Nelarabine—Paraesthesia—Leflunomide—systemic scleroderma	0.000114	0.0011	CcSEcCtD
Nelarabine—Chest pain—Lisinopril—systemic scleroderma	0.000114	0.0011	CcSEcCtD
Nelarabine—Arthralgia—Lisinopril—systemic scleroderma	0.000114	0.0011	CcSEcCtD
Nelarabine—Myalgia—Lisinopril—systemic scleroderma	0.000114	0.0011	CcSEcCtD
Nelarabine—Back pain—Mycophenolate mofetil—systemic scleroderma	0.000113	0.0011	CcSEcCtD
Nelarabine—Dyspnoea—Leflunomide—systemic scleroderma	0.000113	0.0011	CcSEcCtD
Nelarabine—Hypotension—Mycophenolic acid—systemic scleroderma	0.000113	0.0011	CcSEcCtD
Nelarabine—Lethargy—Methotrexate—systemic scleroderma	0.000112	0.00109	CcSEcCtD
Nelarabine—Vomiting—Mometasone—systemic scleroderma	0.000111	0.00108	CcSEcCtD
Nelarabine—Feeling abnormal—Azathioprine—systemic scleroderma	0.000111	0.00107	CcSEcCtD
Nelarabine—Asthenia—Captopril—systemic scleroderma	0.00011	0.00107	CcSEcCtD
Nelarabine—Decreased appetite—Leflunomide—systemic scleroderma	0.00011	0.00107	CcSEcCtD
Nelarabine—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.00011	0.00107	CcSEcCtD
Nelarabine—Osteoarthritis—Methotrexate—systemic scleroderma	0.00011	0.00107	CcSEcCtD
Nelarabine—Confusional state—Lisinopril—systemic scleroderma	0.00011	0.00106	CcSEcCtD
Nelarabine—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.00011	0.00106	CcSEcCtD
Nelarabine—Headache—Mometasone—systemic scleroderma	0.00011	0.00106	CcSEcCtD
Nelarabine—Tremor—Mycophenolate mofetil—systemic scleroderma	0.00011	0.00106	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000109	0.00106	CcSEcCtD
Nelarabine—Insomnia—Mycophenolic acid—systemic scleroderma	0.000109	0.00106	CcSEcCtD
Nelarabine—Fatigue—Leflunomide—systemic scleroderma	0.000109	0.00106	CcSEcCtD
Nelarabine—Oedema—Lisinopril—systemic scleroderma	0.000109	0.00106	CcSEcCtD
Nelarabine—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.000109	0.00105	CcSEcCtD
Nelarabine—Pain—Leflunomide—systemic scleroderma	0.000108	0.00105	CcSEcCtD
Nelarabine—Constipation—Leflunomide—systemic scleroderma	0.000108	0.00105	CcSEcCtD
Nelarabine—Infection—Lisinopril—systemic scleroderma	0.000108	0.00105	CcSEcCtD
Nelarabine—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.000108	0.00105	CcSEcCtD
Nelarabine—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000108	0.00105	CcSEcCtD
Nelarabine—Somnolence—Mycophenolic acid—systemic scleroderma	0.000107	0.00104	CcSEcCtD
Nelarabine—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000107	0.00103	CcSEcCtD
Nelarabine—Neutropenia—Prednisone—systemic scleroderma	0.000106	0.00103	CcSEcCtD
Nelarabine—Abdominal pain—Azathioprine—systemic scleroderma	0.000106	0.00103	CcSEcCtD
Nelarabine—Body temperature increased—Azathioprine—systemic scleroderma	0.000106	0.00103	CcSEcCtD
Nelarabine—Diarrhoea—Captopril—systemic scleroderma	0.000105	0.00102	CcSEcCtD
Nelarabine—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000105	0.00102	CcSEcCtD
Nelarabine—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000105	0.00101	CcSEcCtD
Nelarabine—Feeling abnormal—Leflunomide—systemic scleroderma	0.000104	0.00101	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000104	0.00101	CcSEcCtD
Nelarabine—Fatigue—Mycophenolic acid—systemic scleroderma	0.000104	0.00101	CcSEcCtD
Nelarabine—Nausea—Mometasone—systemic scleroderma	0.000104	0.00101	CcSEcCtD
Nelarabine—Anorexia—Lisinopril—systemic scleroderma	0.000104	0.00101	CcSEcCtD
Nelarabine—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000104	0.00101	CcSEcCtD
Nelarabine—Ataxia—Methotrexate—systemic scleroderma	0.000103	0.001	CcSEcCtD
Nelarabine—Constipation—Mycophenolic acid—systemic scleroderma	0.000103	0.001	CcSEcCtD
Nelarabine—Pain—Mycophenolic acid—systemic scleroderma	0.000103	0.001	CcSEcCtD
Nelarabine—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000103	0.000997	CcSEcCtD
Nelarabine—Hyperglycaemia—Prednisone—systemic scleroderma	0.000103	0.000995	CcSEcCtD
Nelarabine—Cough—Mycophenolate mofetil—systemic scleroderma	0.000102	0.000989	CcSEcCtD
Nelarabine—Hypotension—Lisinopril—systemic scleroderma	0.000102	0.000987	CcSEcCtD
Nelarabine—Dizziness—Captopril—systemic scleroderma	0.000102	0.000986	CcSEcCtD
Nelarabine—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000101	0.000982	CcSEcCtD
Nelarabine—Depression—Prednisone—systemic scleroderma	0.000101	0.000981	CcSEcCtD
Nelarabine—Abdominal pain—Leflunomide—systemic scleroderma	0.0001	0.000972	CcSEcCtD
Nelarabine—Body temperature increased—Leflunomide—systemic scleroderma	0.0001	0.000972	CcSEcCtD
Nelarabine—Feeling abnormal—Mycophenolic acid—systemic scleroderma	9.96e-05	0.000966	CcSEcCtD
Nelarabine—Arthralgia—Mycophenolate mofetil—systemic scleroderma	9.95e-05	0.000965	CcSEcCtD
Nelarabine—Chest pain—Mycophenolate mofetil—systemic scleroderma	9.95e-05	0.000965	CcSEcCtD
Nelarabine—Myalgia—Mycophenolate mofetil—systemic scleroderma	9.95e-05	0.000965	CcSEcCtD
Nelarabine—Neuropathy peripheral—Prednisone—systemic scleroderma	9.94e-05	0.000964	CcSEcCtD
Nelarabine—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	9.92e-05	0.000962	CcSEcCtD
Nelarabine—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	9.89e-05	0.000959	CcSEcCtD
Nelarabine—Insomnia—Lisinopril—systemic scleroderma	9.85e-05	0.000955	CcSEcCtD
Nelarabine—Paraesthesia—Lisinopril—systemic scleroderma	9.78e-05	0.000948	CcSEcCtD
Nelarabine—Vomiting—Captopril—systemic scleroderma	9.78e-05	0.000948	CcSEcCtD
Nelarabine—Dyspnoea—Lisinopril—systemic scleroderma	9.71e-05	0.000942	CcSEcCtD
Nelarabine—Somnolence—Lisinopril—systemic scleroderma	9.68e-05	0.000939	CcSEcCtD
Nelarabine—Headache—Captopril—systemic scleroderma	9.63e-05	0.000934	CcSEcCtD
Nelarabine—Confusional state—Mycophenolate mofetil—systemic scleroderma	9.62e-05	0.000933	CcSEcCtD
Nelarabine—Body temperature increased—Mycophenolic acid—systemic scleroderma	9.56e-05	0.000927	CcSEcCtD
Nelarabine—Abdominal pain—Mycophenolic acid—systemic scleroderma	9.56e-05	0.000927	CcSEcCtD
Nelarabine—Oedema—Mycophenolate mofetil—systemic scleroderma	9.54e-05	0.000925	CcSEcCtD
Nelarabine—Infection—Mycophenolate mofetil—systemic scleroderma	9.48e-05	0.000919	CcSEcCtD
Nelarabine—Decreased appetite—Lisinopril—systemic scleroderma	9.47e-05	0.000918	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Lisinopril—systemic scleroderma	9.4e-05	0.000912	CcSEcCtD
Nelarabine—Fatigue—Lisinopril—systemic scleroderma	9.39e-05	0.000911	CcSEcCtD
Nelarabine—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	9.36e-05	0.000907	CcSEcCtD
Nelarabine—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	9.34e-05	0.000906	CcSEcCtD
Nelarabine—Constipation—Lisinopril—systemic scleroderma	9.31e-05	0.000903	CcSEcCtD
Nelarabine—Pain—Lisinopril—systemic scleroderma	9.31e-05	0.000903	CcSEcCtD
Nelarabine—Diarrhoea—Azathioprine—systemic scleroderma	9.18e-05	0.000891	CcSEcCtD
Nelarabine—Nausea—Captopril—systemic scleroderma	9.13e-05	0.000886	CcSEcCtD
Nelarabine—Anorexia—Mycophenolate mofetil—systemic scleroderma	9.1e-05	0.000882	CcSEcCtD
Nelarabine—Asthenia—Leflunomide—systemic scleroderma	9.09e-05	0.000882	CcSEcCtD
Nelarabine—Feeling abnormal—Lisinopril—systemic scleroderma	8.97e-05	0.00087	CcSEcCtD
Nelarabine—Connective tissue disorder—Prednisone—systemic scleroderma	8.95e-05	0.000868	CcSEcCtD
Nelarabine—Hypotension—Mycophenolate mofetil—systemic scleroderma	8.92e-05	0.000865	CcSEcCtD
Nelarabine—Gastrointestinal pain—Lisinopril—systemic scleroderma	8.91e-05	0.000864	CcSEcCtD
Nelarabine—Neutropenia—Methotrexate—systemic scleroderma	8.89e-05	0.000862	CcSEcCtD
Nelarabine—Dizziness—Azathioprine—systemic scleroderma	8.88e-05	0.000861	CcSEcCtD
Nelarabine—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	8.69e-05	0.000843	CcSEcCtD
Nelarabine—Asthenia—Mycophenolic acid—systemic scleroderma	8.68e-05	0.000841	CcSEcCtD
Nelarabine—Diarrhoea—Leflunomide—systemic scleroderma	8.67e-05	0.000841	CcSEcCtD
Nelarabine—Insomnia—Mycophenolate mofetil—systemic scleroderma	8.63e-05	0.000837	CcSEcCtD
Nelarabine—Abdominal pain—Lisinopril—systemic scleroderma	8.61e-05	0.000835	CcSEcCtD
Nelarabine—Body temperature increased—Lisinopril—systemic scleroderma	8.61e-05	0.000835	CcSEcCtD
Nelarabine—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	8.57e-05	0.000831	CcSEcCtD
Nelarabine—Vomiting—Azathioprine—systemic scleroderma	8.53e-05	0.000828	CcSEcCtD
Nelarabine—Pneumonia—Methotrexate—systemic scleroderma	8.53e-05	0.000827	CcSEcCtD
Nelarabine—Eye disorder—Prednisone—systemic scleroderma	8.51e-05	0.000825	CcSEcCtD
Nelarabine—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	8.51e-05	0.000825	CcSEcCtD
Nelarabine—Somnolence—Mycophenolate mofetil—systemic scleroderma	8.48e-05	0.000823	CcSEcCtD
Nelarabine—Infestation NOS—Methotrexate—systemic scleroderma	8.48e-05	0.000822	CcSEcCtD
Nelarabine—Infestation—Methotrexate—systemic scleroderma	8.48e-05	0.000822	CcSEcCtD
Nelarabine—Depression—Methotrexate—systemic scleroderma	8.45e-05	0.00082	CcSEcCtD
Nelarabine—Headache—Azathioprine—systemic scleroderma	8.41e-05	0.000815	CcSEcCtD
Nelarabine—Dizziness—Leflunomide—systemic scleroderma	8.38e-05	0.000813	CcSEcCtD
Nelarabine—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	8.3e-05	0.000804	CcSEcCtD
Nelarabine—Diarrhoea—Mycophenolic acid—systemic scleroderma	8.27e-05	0.000802	CcSEcCtD
Nelarabine—Stomatitis—Methotrexate—systemic scleroderma	8.26e-05	0.000801	CcSEcCtD
Nelarabine—Angiopathy—Prednisone—systemic scleroderma	8.26e-05	0.000801	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	8.24e-05	0.000799	CcSEcCtD
Nelarabine—Pain—Mycophenolate mofetil—systemic scleroderma	8.16e-05	0.000791	CcSEcCtD
Nelarabine—Constipation—Mycophenolate mofetil—systemic scleroderma	8.16e-05	0.000791	CcSEcCtD
Nelarabine—Vomiting—Leflunomide—systemic scleroderma	8.06e-05	0.000782	CcSEcCtD
Nelarabine—Hepatobiliary disease—Methotrexate—systemic scleroderma	8.02e-05	0.000777	CcSEcCtD
Nelarabine—Dizziness—Mycophenolic acid—systemic scleroderma	8e-05	0.000775	CcSEcCtD
Nelarabine—Epistaxis—Methotrexate—systemic scleroderma	7.99e-05	0.000775	CcSEcCtD
Nelarabine—Mental disorder—Prednisone—systemic scleroderma	7.98e-05	0.000774	CcSEcCtD
Nelarabine—Nausea—Azathioprine—systemic scleroderma	7.97e-05	0.000773	CcSEcCtD
Nelarabine—Headache—Leflunomide—systemic scleroderma	7.94e-05	0.00077	CcSEcCtD
Nelarabine—Malnutrition—Prednisone—systemic scleroderma	7.93e-05	0.000769	CcSEcCtD
Nelarabine—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	7.86e-05	0.000763	CcSEcCtD
Nelarabine—Asthenia—Lisinopril—systemic scleroderma	7.81e-05	0.000758	CcSEcCtD
Nelarabine—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	7.8e-05	0.000757	CcSEcCtD
Nelarabine—Vomiting—Mycophenolic acid—systemic scleroderma	7.69e-05	0.000746	CcSEcCtD
Nelarabine—Headache—Mycophenolic acid—systemic scleroderma	7.58e-05	0.000735	CcSEcCtD
Nelarabine—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	7.54e-05	0.000732	CcSEcCtD
Nelarabine—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	7.54e-05	0.000732	CcSEcCtD
Nelarabine—Nausea—Leflunomide—systemic scleroderma	7.53e-05	0.00073	CcSEcCtD
Nelarabine—Urinary tract disorder—Methotrexate—systemic scleroderma	7.51e-05	0.000729	CcSEcCtD
Nelarabine—Vision blurred—Prednisone—systemic scleroderma	7.47e-05	0.000724	CcSEcCtD
Nelarabine—Urethral disorder—Methotrexate—systemic scleroderma	7.46e-05	0.000723	CcSEcCtD
Nelarabine—Diarrhoea—Lisinopril—systemic scleroderma	7.45e-05	0.000723	CcSEcCtD
Nelarabine—Anaemia—Prednisone—systemic scleroderma	7.33e-05	0.00071	CcSEcCtD
Nelarabine—Dizziness—Lisinopril—systemic scleroderma	7.2e-05	0.000698	CcSEcCtD
Nelarabine—Nausea—Mycophenolic acid—systemic scleroderma	7.18e-05	0.000696	CcSEcCtD
Nelarabine—Eye disorder—Methotrexate—systemic scleroderma	7.11e-05	0.00069	CcSEcCtD
Nelarabine—Cardiac disorder—Methotrexate—systemic scleroderma	7.06e-05	0.000685	CcSEcCtD
Nelarabine—Loss of consciousness—Prednisone—systemic scleroderma	6.97e-05	0.000676	CcSEcCtD
Nelarabine—Vomiting—Lisinopril—systemic scleroderma	6.92e-05	0.000672	CcSEcCtD
Nelarabine—Angiopathy—Methotrexate—systemic scleroderma	6.9e-05	0.000669	CcSEcCtD
Nelarabine—Convulsion—Prednisone—systemic scleroderma	6.87e-05	0.000666	CcSEcCtD
Nelarabine—Mediastinal disorder—Methotrexate—systemic scleroderma	6.86e-05	0.000665	CcSEcCtD
Nelarabine—Asthenia—Mycophenolate mofetil—systemic scleroderma	6.85e-05	0.000664	CcSEcCtD
Nelarabine—Chills—Methotrexate—systemic scleroderma	6.83e-05	0.000662	CcSEcCtD
Nelarabine—Headache—Lisinopril—systemic scleroderma	6.82e-05	0.000662	CcSEcCtD
Nelarabine—Arthralgia—Prednisone—systemic scleroderma	6.75e-05	0.000654	CcSEcCtD
Nelarabine—Myalgia—Prednisone—systemic scleroderma	6.75e-05	0.000654	CcSEcCtD
Nelarabine—Mental disorder—Methotrexate—systemic scleroderma	6.67e-05	0.000646	CcSEcCtD
Nelarabine—Malnutrition—Methotrexate—systemic scleroderma	6.62e-05	0.000642	CcSEcCtD
Nelarabine—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	6.53e-05	0.000633	CcSEcCtD
Nelarabine—Dysgeusia—Methotrexate—systemic scleroderma	6.49e-05	0.000629	CcSEcCtD
Nelarabine—Nausea—Lisinopril—systemic scleroderma	6.47e-05	0.000627	CcSEcCtD
Nelarabine—Oedema—Prednisone—systemic scleroderma	6.47e-05	0.000627	CcSEcCtD
Nelarabine—Infection—Prednisone—systemic scleroderma	6.43e-05	0.000623	CcSEcCtD
Nelarabine—Back pain—Methotrexate—systemic scleroderma	6.41e-05	0.000621	CcSEcCtD
Nelarabine—Nervous system disorder—Prednisone—systemic scleroderma	6.34e-05	0.000615	CcSEcCtD
Nelarabine—Dizziness—Mycophenolate mofetil—systemic scleroderma	6.31e-05	0.000612	CcSEcCtD
Nelarabine—Vision blurred—Methotrexate—systemic scleroderma	6.24e-05	0.000605	CcSEcCtD
Nelarabine—Anorexia—Prednisone—systemic scleroderma	6.17e-05	0.000598	CcSEcCtD
Nelarabine—Anaemia—Methotrexate—systemic scleroderma	6.12e-05	0.000594	CcSEcCtD
Nelarabine—Vomiting—Mycophenolate mofetil—systemic scleroderma	6.07e-05	0.000588	CcSEcCtD
Nelarabine—Headache—Mycophenolate mofetil—systemic scleroderma	5.98e-05	0.00058	CcSEcCtD
Nelarabine—Leukopenia—Methotrexate—systemic scleroderma	5.93e-05	0.000575	CcSEcCtD
Nelarabine—Musculoskeletal discomfort—Prednisone—systemic scleroderma	5.89e-05	0.000571	CcSEcCtD
Nelarabine—Insomnia—Prednisone—systemic scleroderma	5.85e-05	0.000567	CcSEcCtD
Nelarabine—Paraesthesia—Prednisone—systemic scleroderma	5.81e-05	0.000563	CcSEcCtD
Nelarabine—Cough—Methotrexate—systemic scleroderma	5.78e-05	0.000561	CcSEcCtD
Nelarabine—Convulsion—Methotrexate—systemic scleroderma	5.74e-05	0.000557	CcSEcCtD
Nelarabine—Nausea—Mycophenolate mofetil—systemic scleroderma	5.67e-05	0.00055	CcSEcCtD
Nelarabine—Myalgia—Methotrexate—systemic scleroderma	5.64e-05	0.000547	CcSEcCtD
Nelarabine—Chest pain—Methotrexate—systemic scleroderma	5.64e-05	0.000547	CcSEcCtD
Nelarabine—Arthralgia—Methotrexate—systemic scleroderma	5.64e-05	0.000547	CcSEcCtD
Nelarabine—Decreased appetite—Prednisone—systemic scleroderma	5.62e-05	0.000545	CcSEcCtD
Nelarabine—Fatigue—Prednisone—systemic scleroderma	5.58e-05	0.000541	CcSEcCtD
Nelarabine—Constipation—Prednisone—systemic scleroderma	5.53e-05	0.000536	CcSEcCtD
Nelarabine—Confusional state—Methotrexate—systemic scleroderma	5.45e-05	0.000529	CcSEcCtD
Nelarabine—Infection—Methotrexate—systemic scleroderma	5.37e-05	0.000521	CcSEcCtD
Nelarabine—Feeling abnormal—Prednisone—systemic scleroderma	5.33e-05	0.000517	CcSEcCtD
Nelarabine—Nervous system disorder—Methotrexate—systemic scleroderma	5.3e-05	0.000514	CcSEcCtD
Nelarabine—Thrombocytopenia—Methotrexate—systemic scleroderma	5.29e-05	0.000513	CcSEcCtD
Nelarabine—Gastrointestinal pain—Prednisone—systemic scleroderma	5.29e-05	0.000513	CcSEcCtD
Nelarabine—Anorexia—Methotrexate—systemic scleroderma	5.15e-05	0.0005	CcSEcCtD
Nelarabine—Abdominal pain—Prednisone—systemic scleroderma	5.11e-05	0.000496	CcSEcCtD
Nelarabine—Body temperature increased—Prednisone—systemic scleroderma	5.11e-05	0.000496	CcSEcCtD
Nelarabine—Hypotension—Methotrexate—systemic scleroderma	5.05e-05	0.00049	CcSEcCtD
Nelarabine—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	4.93e-05	0.000478	CcSEcCtD
Nelarabine—Insomnia—Methotrexate—systemic scleroderma	4.89e-05	0.000474	CcSEcCtD
Nelarabine—Paraesthesia—Methotrexate—systemic scleroderma	4.85e-05	0.000471	CcSEcCtD
Nelarabine—Dyspnoea—Methotrexate—systemic scleroderma	4.82e-05	0.000467	CcSEcCtD
Nelarabine—Somnolence—Methotrexate—systemic scleroderma	4.81e-05	0.000466	CcSEcCtD
Nelarabine—Decreased appetite—Methotrexate—systemic scleroderma	4.7e-05	0.000456	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Methotrexate—systemic scleroderma	4.67e-05	0.000453	CcSEcCtD
Nelarabine—Fatigue—Methotrexate—systemic scleroderma	4.66e-05	0.000452	CcSEcCtD
Nelarabine—Asthenia—Prednisone—systemic scleroderma	4.64e-05	0.00045	CcSEcCtD
Nelarabine—Pain—Methotrexate—systemic scleroderma	4.62e-05	0.000448	CcSEcCtD
Nelarabine—Feeling abnormal—Methotrexate—systemic scleroderma	4.45e-05	0.000432	CcSEcCtD
Nelarabine—Diarrhoea—Prednisone—systemic scleroderma	4.43e-05	0.000429	CcSEcCtD
Nelarabine—Gastrointestinal pain—Methotrexate—systemic scleroderma	4.42e-05	0.000429	CcSEcCtD
Nelarabine—Dizziness—Prednisone—systemic scleroderma	4.28e-05	0.000415	CcSEcCtD
Nelarabine—Abdominal pain—Methotrexate—systemic scleroderma	4.27e-05	0.000414	CcSEcCtD
Nelarabine—Body temperature increased—Methotrexate—systemic scleroderma	4.27e-05	0.000414	CcSEcCtD
Nelarabine—Vomiting—Prednisone—systemic scleroderma	4.11e-05	0.000399	CcSEcCtD
Nelarabine—Headache—Prednisone—systemic scleroderma	4.05e-05	0.000393	CcSEcCtD
Nelarabine—Asthenia—Methotrexate—systemic scleroderma	3.88e-05	0.000376	CcSEcCtD
Nelarabine—Nausea—Prednisone—systemic scleroderma	3.84e-05	0.000373	CcSEcCtD
Nelarabine—Diarrhoea—Methotrexate—systemic scleroderma	3.7e-05	0.000359	CcSEcCtD
Nelarabine—Dizziness—Methotrexate—systemic scleroderma	3.57e-05	0.000347	CcSEcCtD
Nelarabine—Vomiting—Methotrexate—systemic scleroderma	3.44e-05	0.000333	CcSEcCtD
Nelarabine—Headache—Methotrexate—systemic scleroderma	3.39e-05	0.000328	CcSEcCtD
Nelarabine—Nausea—Methotrexate—systemic scleroderma	3.21e-05	0.000311	CcSEcCtD
